주장 점검
환자에게 보이는 주장과 근거
이 페이지는 위험도가 높은 주장, 미해결 주장, 검토가 필요한 주장을 추적합니다. 안전 시스템의 일부입니다.
supported
approval
Tunlametinib / HL-085 has China NMPA conditional approval in the source-cited NRAS-mutant advanced melanoma context after anti-PD-1/PD-L1 failure.
risk: highpatient-facingreviewer needed
supported
mechanism
Tunlametinib / HL-085 is described as a selective MEK1/2 inhibitor.
risk: mediumpatient-facing
unresolved
uncertainty
The exact tunlametinib plus nivolumab melanoma trial/publication has not been found and must remain an unresolved lived-context lead.
risk: highpatient-facingreviewer needed
supported
patient-safety
A trial listing match does not mean the trial fits.
risk: highpatient-facing
supported
approval
Lifileucel has FDA accelerated approval in the source-cited unresectable or metastatic melanoma context.
risk: highpatient-facingreviewer needed